Aktiia becomes Hilo and raises USD 42 million to accelerate global expansion

Neuchâtel health tech company Aktiia has announced its rebranding to Hilo, alongside the closing of a USD 42 million Series B funding round. The new capital will support the international growth of its cuffless blood pressure monitoring platform and further product development.

Based in Neuchâtel, Hilo has built a strong reputation for its medical-grade blood pressure monitoring solutions. Known until now as Aktiia, the company had previously received CE mark approval for its CALFREE optical technology, which allows blood pressure to be measured via smartphone cameras or smartwatches without the need for a cuff. That development positioned the company as a leader in the emerging cuffless blood pressure monitoring (CBPM) segment.

With over 120,000 devices sold and a proprietary machine learning model trained on tens of billions of optical signals, Hilo has created one of the most robust blood pressure datasets in the sector. This foundation has enabled the company to pursue new clinical applications and consumer integrations, including ongoing regulatory efforts in the U.S. and other markets.

The oversubscribed Series B round, co-led by Earlybird Health and Wellington Partners, brings Hilo’s total funding to over USD 100 million. New investors Kfund and naturalX Health Ventures joined the round, along with continued support from existing backers such as Khosla Ventures and redalpine.

The funding will support expansion into key markets, including Germany, and allow for the launch of new marketing and education initiatives. It will also accelerate the development of Hilo’s enterprise-ready blood pressure intelligence platform.

The rebrand reflects the company’s ambition to make clinically validated, cuffless blood pressure monitoring universally accessible. In the company’s press release, CEO Raghav “Rags” Gupta emphasized that the name Hilo signals a renewed commitment to empowering users with smart tools to better manage hypertension, a global health issue affecting more than a billion people worldwide.